arrow
J

Jeong Heo

free university of berlin
H指数:47
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discordant Antitumor Efficacy with Compromised Survival in High-Risk Unresectable Hepatocellular Carcinoma

高风险不可切除肝细胞癌中不一致的抗肿瘤疗效与受损的生存期

Cancers
IF4.4
2026-09-110
OA
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies

塞拉德尔帕(Seladelpar)在原发性胆汁性胆管炎合并代偿期肝硬化患者中的疗效与安全性:来自RESPONSE和ASSURE研究的数据

2026-05-010
PRE
Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial

Elbsiran和PEG-IFNα用于慢性乙型肝炎感染:一项部分随机、开放标签、II期试验

2025-11-070
OAAI
Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C

口服抗病毒药物后肝脏硬度测量可有效预测慢性丙型肝炎患者发生HCC的风险

2025-09-080
OAAI
Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)

索磷布韦为基础治疗慢性丙型肝炎患者后的长期肝脏及肝外结局(LONGHEAD研究)

2025-04-100
OA
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB
2024-12-010
PRE
Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

EMERALD-1研究中基线肿瘤负荷对结局的影响:一项关于度伐利尤单抗(D)±贝伐珠单抗(B)联合经动脉化疗栓塞(TACE)在栓塞适应症的不可切除肝细胞癌(uHCC)中的III期研究

2024-12-011
PRE
Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Interim Results for 2 Years From the ASSURE Study

开放标签下塞拉德帕治疗原发性胆汁性胆管炎的长期有效性与安全性:ASSURE研究2年期的中期结果

2024-10-010
PRE
Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study

Fostrox(fostroxacitabine bralpamide)联合仑伐替尼治疗既往接受免疫联合疗法后进展的局部晚期不可切除或转移性肝细胞癌(HCC)患者:一项多中心 Ib/IIa 期研究的结果

2024-09-010
PRE
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study

切换到替诺福韦alafenamide患者病毒学抑制慢性乙型肝炎和肾或肝损害: 最后一周96结果从开放标签,多中心,2期研究

2024-08-011
PRE
Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
2024-06-010
PRE
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial

阿特珠单抗联合贝伐单抗与主动监测在切除或消融高危肝细胞癌患者中的比较 (IMbrave050): 一项随机、开放标签、多中心、3期试验

LANCET
IF88.5
2023-11-01144
PRE